Abstract
The innate immune system is the first line of host defense against infectious agents. There are many variations of response in individuals. Immunology has already been playing an important role in personalization of therapy, e.g. blood grouping and cross-matching for blood transfusion.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54:3782–9.
Fu Liang NG, Holt DW, MacPhee I. Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. Expert Opin Pharmacother. 2007;8:2045–58.
Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis. 2014; pii: annrheumdis-2013-204986.
Hronová K, Å Ãma M, SvÄ›tlÃk S, et al. Pharmacogenetics and immunosuppressive drugs. Expert Rev Clin Pharmacol. 2014;7:821–35.
Huizinga TW. Personalized medicine in rheumatoid arthritis: is the glass half full or half empty. J Int Med. 2014. doi:10.1111/joim.12319.
Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436:709–13.
Liu Y, Aryee MJ, Padyukov L, et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotech. 2013;31:142–7.
Paczesny S, Braun TM, Levine JE. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010;2:13ra2.
Pieringer H, Studnicka-Benke A. What is causing my arthritis, doctor? A glimpse beyond the usual suspects in the pathogenesis of rheumatoid arthritis. QJM. 2013;106:219–28.
Plenge RM, Seielstad M, Padyukov L, et al. TRAF1–C5 as a risk locus for rheumatoid arthritis – a genomewide study. N Engl J Med. 2007;357:1199–209.
Sarwal MM. Deconvoluting the ’omics for organ transplantation. Curr Opin Organ Transplant. 2009;14:544–51.
Taniguchi A, Urano W, Tanaka E, Kamatani N. Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis. Nippon Rinsho. 2007;65:371–9.
Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369:529–39.
Xie X, Zhang D, Chen JW, et al. Pharmacogenomics of biological treatment in rheumatoid arthritis. Expert Opin Biol Ther. 2014;14:157–64.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Jain, K.K. (2015). Personalized Approaches to Immune Disorders. In: Textbook of Personalized Medicine. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2553-7_17
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2553-7_17
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2552-0
Online ISBN: 978-1-4939-2553-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)